620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

2021 ◽  
Vol 32 ◽  
pp. S657-S659
Author(s):  
E. Shenderov ◽  
G.H.G. Mallesara ◽  
P.J. Wysocki ◽  
W. Xu ◽  
R. Ramlau ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Preliminary Results ◽  
Drug Conjugate ◽  
Antibody Drug

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2511-2511 ◽  
Author(s):  
Carlos Alberto Gomez-Roca ◽  
Valentina Boni ◽  
Victor Moreno ◽  
John Charles Morris ◽  
Jean-Pierre Delord ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors

2019 ◽  
Vol 145 (7) ◽  
pp. 1798-1808 ◽  
Author(s):  
Ignacio Garrido-Laguna ◽  
Ian Krop ◽  
Howard A. Burris ◽  
Erika Hamilton ◽  
Fadi Braiteh ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document